STOCK TITAN

Avid Bioservices - CDMO STOCK NEWS

Welcome to our dedicated page for Avid Bioservices news (Ticker: CDMO), a resource for investors and traders seeking the latest updates and insights on Avid Bioservices stock.

Company Overview

Avid Bioservices (symbol: CDMO) operates as a dedicated Contract Development and Manufacturing Organization (CDMO) specializing in the production of complex biologics. With an extensive legacy in manufacturing monoclonal antibodies, recombinant proteins, and enzymes using mammalian cell culture, the company offers comprehensive, end‐to‐end solutions that cater to the intricate needs of biotechnology and pharmaceutical companies. Emphasizing cGMP manufacturing, bioprocess optimization, and rigorous regulatory compliance, Avid Bioservices has established itself as a trusted partner through decades of focused expertise in the biologics sector.

Core Capabilities and Services

The company spans the entirety of the biologics development continuum, providing customized services that address both early-stage process development and full-scale commercial manufacturing. Key areas of service include:

  • Process Development: Offering cell line development, upstream and downstream process optimization, and analytical methods development to ensure robust and scalable production.
  • Clinical and Commercial Manufacturing: Delivering tailored cGMP manufacturing solutions that cover drug substance production, bulk packaging, and quality control testing, thereby supporting clinical trials as well as commercial supply chains.
  • Regulatory and Quality Support: Assisting clients with regulatory submission support and stability testing, ensuring that all processes meet stringent global quality benchmarks.

Technical Expertise and Industry Position

Avid Bioservices combines decades of deep technical knowledge with state‐of‐the‐art facilities, which allows the company to navigate the full lifecycle of biologic products. Its robust integration of process development and manufacturing expertise is underscored by strategic investments in technology and capacity expansion. This positions Avid as a reliable partner in an industry where quality, scalability, and regulatory adherence are of paramount importance.

Operational Excellence

The company is recognized for its methodical approach to process optimization and risk management. By aligning operational practices with the evolving needs of the biopharmaceutical landscape, Avid Bioservices ensures efficiency and consistency in the production of high-quality biologics. Their operational model is underpinned by:

  • Customizable Solutions: Tailoring services to the individual requirements of each client, from investigative research to commercial launch.
  • Integrated Service Offerings: Combining process development, manufacturing, and quality control under one roof to streamline production and simplify regulatory compliance.
  • Global Regulatory Compliance: Adhering to comprehensive quality systems and cGMP guidelines, which demonstrates the company’s commitment to maintaining high industry standards.

Market Significance and Competitive Landscape

Operating in a rapidly evolving biopharmaceutical market, Avid Bioservices has carved out a niche by consistently delivering end-to-end solutions that meet the complex demands of early stage research and later stage commercialization. Its service model is geared towards mitigating manufacturing risks while offering scalable production capabilities. The company’s focus on technical excellence and regulatory expertise differentiates it from other players in the CDMO sector, making it a key strategic partner for both emerging biotech innovators and established pharmaceutical companies.

Why Avid Bioservices?

Clients choose Avid Bioservices for its holistic approach to biologics manufacturing coupled with a long history of operational excellence. The integration of development and commercial manufacturing streamlines the transition from concept to market, ensuring that each biologic undergoes a rigorous quality process. This blend of expertise and comprehensive service offerings underlines the company’s ability to consistently deliver on its promise of high-quality, reliable production essential for the advancement of modern therapeutics.

Areas of Expertise

To summarize, Avid Bioservices excels in:

  • Biologics Process Development and Optimization
  • cGMP Clinical and Commercial Manufacturing
  • Comprehensive Regulatory and Quality Support
  • Tailored Service Offerings for Biotech and Pharma Clients

The company’s enduring commitment to quality and operational integrity, combined with advanced technological capabilities, makes Avid Bioservices a critical component in the development and manufacturing of modern biologic therapies. Its methodical and integrated approach provides companies with efficient access to innovative treatments, underscoring its pivotal role in the biopharmaceutical supply chain.

Rhea-AI Summary
Avid Bioservices, Inc. (CDMO) plans to offer $160 million in Convertible Senior Notes due 2029 to qualified institutional buyers. The company aims to use the net proceeds to repurchase or repay its 2026 Notes, potentially impacting the market price of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.6%
Tags
none
-
Rhea-AI Summary
Avid Bioservices, Inc. (NASDAQ:CDMO) announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024. Revenues decreased by 11% in the third quarter but increased by 33% compared to the previous quarter. The company signed new orders totaling $41 million, resulting in a record high revenue backlog of $206 million. Gross profit margins decreased due to fewer manufacturing runs and increased costs. SG&A expenses decreased by 10% in the third quarter. Operating loss was $4.0 million for the quarter. Avid is maintaining revenue guidance for the full fiscal year 2024 and completed its CGT facility expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.6%
Tags
-
Rhea-AI Summary
Avid Bioservices, Inc. (NASDAQ:CDMO) recorded second quarter revenue of $25.4 million, signed $35 million in net new business orders, entered into a partnership with California Institute of Regenerative Medicine, and completed construction of a cell and gene therapy facility. However, the company is adjusting fiscal 2024 revenue guidance to $137 to $147 million, representing a decrease compared to prior projections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.29%
Tags
Rhea-AI Summary
Avid Bioservices, Inc. (NASDAQ:CDMO) to Report Q2 Fiscal Year 2024 Financial Results on December 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences earnings
-
Rhea-AI Summary
Avid Bioservices, Inc. (NASDAQ:CDMO) has partnered with the California Institute for Regenerative Medicine (CIRM) to provide its world-class cell and gene therapy (CGT) CDMO services to support clinical development activities. This collaboration aims to accelerate gene therapy development and manufacturing for CIRM-funded programs, reducing timelines required to advance through clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.3%
Tags
partnership
-
Rhea-AI Summary
Avid Bioservices completes construction of CGMP manufacturing suites within its new CGT facility
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
none
Rhea-AI Summary
Avid Bioservices to participate in RBC Capital Markets Virtual CDMO Conference on October 2-3, 2023. Nick Green, CEO, will be the featured speaker in a fireside chat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
-
Rhea-AI Summary
Avid Bioservices reports Q1 revenue of $37.7M, a 3% increase YoY. Backlog increases to $189M. Cell and gene therapy facility expansion on track for Q3 2023 opening. Revenue guidance for FY 2024 remains at $145M-$165M. Net loss of $2.1M in Q1. Cash and cash equivalents at $24.9M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
-
Rhea-AI Summary
Avid Bioservices to report Q1 FY2024 financial results on September 7, 2023, and host a webcast. Senior management will discuss financial results and recent corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.75%
Tags

FAQ

What is the current stock price of Avid Bioservices (CDMO)?

The current stock price of Avid Bioservices (CDMO) is $12.49 as of February 7, 2025.

What is the market cap of Avid Bioservices (CDMO)?

The market cap of Avid Bioservices (CDMO) is approximately 798.9M.

What are the primary services offered by Avid Bioservices?

Avid Bioservices provides a comprehensive range of services including process development, cGMP clinical and commercial manufacturing, and regulatory support for biologics. Their offerings span from early-stage cell line development to full-scale commercialization production.

How does Avid Bioservices ensure quality in its manufacturing processes?

The company adheres to stringent cGMP guidelines and employs advanced quality control systems to maintain high standards throughout the manufacturing process. Their integrated approach includes rigorous analytical testing, stability assessments, and detailed regulatory support.

What sets Avid Bioservices apart from other CDMOs?

Avid Bioservices distinguishes itself through its extensive experience in both development and manufacturing of biologics. Their capability to offer end-to-end solutions—from cell line development to commercial manufacturing—and commitment to regulatory compliance make them a preferred partner in the biopharmaceutical industry.

What types of biologic products does Avid Bioservices manufacture?

The company specializes in the production of complex biologics such as monoclonal antibodies, recombinant proteins, and enzymes. These products are developed using advanced mammalian cell culture techniques to ensure high quality and clinical efficacy.

How does Avid Bioservices support early-stage development programs?

For early-stage programs, Avid offers a variety of process development activities that include cell line development, upstream and downstream process optimization, and analytical method development. This support is designed to mitigate risks and ensure a smooth transition from research to clinical manufacturing.

How does Avid Bioservices maintain regulatory compliance?

The company maintains a strong track record of regulatory compliance by integrating quality systems throughout all stages of product development and manufacturing. Their dedicated regulatory support services help clients navigate the complexities of global health agency requirements.
Avid Bioservices

Nasdaq:CDMO

CDMO Rankings

CDMO Stock Data

798.90M
62.86M
1.13%
104.32%
18.2%
Biotechnology
Pharmaceutical Preparations
Link
United States
TUSTIN